A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

Jatin Patel,Damon Bass,Albertus Beishuizen,Xavier Bocca Ruiz,Hatem Boughanmi,Anthony Cahn,Hugo Colombo,Gerard J. Criner,Katherine Davy,Javier de-Miguel-Díez,Pablo A. Doreski,Sofia Fernandes,Bruno François,Anubha Gupta,Kate Hanrott,Timothy Hatlen,Dave Inman,John D. Isaacs,Emily Jarvis,Natalia Kostina,Tatiana Kropotina,Jean-Claude Lacherade,Divya Lakshminarayanan,Pedro Martinez-Ayala,Charlene McEvoy,Ferhat Meziani,Mehran Monchi,Sumanta Mukherjee,Rosana Muñoz-Bermúdez,Jessica Neisen,Ciara O'Shea,Gaëtan Plantefeve,Lorrie Schifano,Lee E. Schwab,Zainab Shahid,Michinori Shirano,Julia E. Smith,Eduardo Sprinz,Charlotte Summers,Nicolas Terzi,Mark A. Tidswell,Yuliya Trefilova,Russell Williamson,Duncan Wyncoll,Mark Layton

DOI: https://doi.org/10.1183/13993003.01870-2021

2023-02-02

ERS Monograph

Abstract:Background Granulocyte–macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19. Methods In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18–79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28. Results In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28 versus 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI –0.8–11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2–33.1%, p=0.009) was observed in the predefined 70–79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI –9.3–11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19. Conclusions There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.